All In Biotech

Drug Trial Radar · NCT07948109

YSCH-01 for Recurrent or Progressive Glioblastoma

A Single-Arm, Open-Label, Dose-Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of YSCH-01 in Subjects With Recurrent or Progressive Glioblastoma

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Nov 10, 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label dose-escalation and dose-expansion study that plans to enroll 16 to 32 adult participants with recurrent or progressive glioblastoma. Participants will be assigned to different dose groups. This study consists of two parts, namely the dose escalation stage and the dose expansion stage. The study aims to determine the safety and tolerability of the oncolytic adenovirus YSCH-01 in adult participants with recurrent or progressive glioblastoma.

Conditions

  • Recurrent Glioblastoma (WHO-Grade IV Glioma)
  • Progressive Glioblastoma
  • Recurrent Glioblastoma

Interventions

  • YSCH-01Drug

    After being enrolled, the participants underwent tumor biopsy/ resection and then an Ommaya reservoir was implanted into the tumor. The participants would receive single-agent treatment with YSCH-01 every 3 weeks. YSCH-01 was administered within the tumor through the implanted Ommaya reservoir.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLT)Time frame: 21 days after the first dose and 21 days after the second dose
  2. Safety and tolerability assessed by Adverse Events (AEs)Time frame: From first dose up to 28 days after last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.